Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - phenytoin sodium, quantity: 100 mg - injection, solution - excipient ingredients: propylene glycol; water for injections; ethanol absolute; hydrochloric acid; sodium hydroxide - for the control of status epilepticus, tonic-clonic (grand mal), psychomotor seizures and the prevention of seizures occurring during or following neurosurgery. phenytoin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, phenytoin frequently improves the mental condition and outlook of epileptic patients. it has also been used in the treatment of certain cardiac arrhythmias, particularly in those patients who do not respond to conventional antiarrhythmic agents or to cardioversion. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration)

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australia - English - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - fosnetupitant chloride hydrochloride, quantity: 260 mg (equivalent: fosnetupitant, qty 235 mg); palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, concentrated - excipient ingredients: sodium hydroxide; mannitol; disodium edetate; hydrochloric acid; water for injections - indicated in adult patients for:,prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.,prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - irinotecan hydrochloride trihydrate, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: distearoylphosphatidylcholine; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; hepes; sodium chloride; water for injections; sucrosofate - onivyde is indicated:,? in combination with oxaliplatin and 5 fluorouracil (5 fu) and leucovorin (lv) for the first-line treatment of metastatic pancreatic adenocarcinoma.,? in combination with 5-fu and lv for the treatment of metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 1.09 mg (equivalent: topotecan, qty 1 mg) - injection, concentrated - excipient ingredients: tartaric acid; hydrochloric acid; sodium hydroxide; water for injections - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 4.346 mg (equivalent: topotecan, qty 4 mg) - injection, concentrated - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; tartaric acid - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - mivacurium chloride, quantity: 2.14 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections - mivacron is a highly selective, non-depolarising neuromuscular blocking agent with a fast recovery profile and a short duration of action. mivacron is used as an adjunct to general anaesthesia to relax skeletal muscles and to facilitate tracheal intubation and mechanical ventilation. this formulation contains no antimicrobial preservative and is intended for single patient use.